Abstract
Introduction
Posttransplant lymphoproliferative disorder (PTLD) constitutes a heterogeneous group of diseases. We summarize the experience of our hospital, one of Spain’s largest series of renal (294), liver (47) and allogeneic stem cell transplants (67), where four cases of PTLD have developed related to complex viral infections.
Methods
Case 1 was a 24-month-old boy diagnosed with acute lymphoblastic leukemia who underwent allogeneic stem-cell transplantation (SCT). He was seropositive for Epstein-Barr virus (EBV) and developed an aggressive B-cell non-Hodgkin’s lymphoma (B-NHL) related to EBV reactivation and human herpesvirus 6 (HHV-6) infection. Cases 2, 3, and 4 developed after kidney transplantation and were all EBV seronegative. Case 2 had associated cytomegalovirus (CMV) and EBV infection. Cases 3 and 4 only revealed EBV viral load. Cases 1, 3, and 4 progressed rapidly, with fatal outcome. Global incidence of PTLD in our series is 1.1%.
Conclusion
PTLD is a rare but life-threatening condition. Although EBV plays a clear role in its pathogenesis, other associated viral infections could trigger this situation. Current therapies include rituximab, decreasing immunosuppressive drugs. and conventional chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Opelz G, Schwarz V, Wujciak T et al (1995) Analysis of non-Hodgkin’s lymphomas in organ transplant recipients. Transplant Rev 9:231–240
Dharnidharka VR, Sullivan EK, Stablein DM et al (2001) Risk factors for post transplant lymphoproliferative disorder (PTLD) in kidney transplantation: a report of the North America Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065–1068
Collins MH, Montone KT, Leahey AM et al (2001) Post-transplant lymphoproliferative disease in children. Pediatr Transplantation 5:250–257
van Esser JW, van der Holt B, Meijer E et al (2001) Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell depleted SCT. Blood 98(4):972–978
Cockfield SM (2001) Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3:70–80
Shapiro R, Nalesnik M, McCauley J et al (1999) Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant recipient receiving tacrolimus based immunosuppression. Transplantation 68:1851–1854
Razonable R, Paya C (2003) Herpesvirus infections in transplant recipients: current challenges in the clinical management or Cytomegalovirus and Epstein-Barr virus infections. Herpes 10(3): 60–65
Manez R, Breinig MC, Linden P et al (1997) Post-transplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J infect Dis 176:1462–1467
Opelz G, Doler B (2003) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Tranplantation 4:222–230
Verchuuren EA, Stevens SJ, van Imhoff GW (2007) Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse and the complication. Transplantation 73:100–104
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vila, L., Moreno, L., Andrés, M.d.M. et al. Could other viruses cause pediatric posttransplant lymphoproliferative disorder?. Clin Transl Oncol 10, 422–425 (2008). https://doi.org/10.1007/s12094-008-0225-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0225-6